Obesity and obesity-related pathologies (such as diabetes, cardiac ischaemia and stroke) represent an important health issue in developed countries. Fibrosis has a crucial role in adipose tissue dysfunction; thus, elucidating its underlying mechanisms could aid the identification of potential therapeutic targets for obesity. The enzymatic activity of lysyl oxidase (LOX) is required for tissue fibrosis and remodelling, but its involvement in adipose tissue dysfunction is still unclear. Here, Victoria Cachofeiro's and Cristina Rodríguez's groups tried to clarify this. They found an increase in LOX expression in tissue samples from morbidly obese individuals and they replicated this finding in obese rats fed a high-fat diet. Interestingly, in these animals the LOX inhibitor β-aminopropionitrile (BAPN) reduces adipose tissue fibrosis, counteracts the increase in body weight and fat mass, and normalises multiple metabolic parameters (including glucose, insulin and triglyceride levels). Moreover, BAPN ameliorates the obesity-related dysfunction of several proteins involved in the control of insulin sensitivity (such as adiponectin, glucose transporter 4 and suppressor of cytokine signalling 3) both in obese rats and in 3T3-L1 adipocytes, an in vitro model of insulin resistance. These results suggest that targeting LOX and tissue fibrosis is a promising strategy to treat adipose tissue dysfunction in obesity. Page 543
A role for LOX in obesity Open Access
A role for LOX in obesity. Dis Model Mech 1 June 2015; 8 (6): e0601. doi:
Download citation file:
Advertisement
Cited by
Call for papers – In Vitro Models of Human Disease to Inform Mechanism and Drug Discovery

We invite you to submit your latest research to our upcoming special issue: In Vitro Models of Human Disease to Inform Mechanism and Drug Discovery, coordinated by DMM Editor Vivian Li (The Francis Crick Institute, London, UK), alongside Guest Editors Austin Smith (University of Exeter, UK) and Joseph Wu (Stanford University School of Medicine, USA).The deadline for submitting articles is 6 October 2025.
The Company of Biologists Workshops

For the last 15 years, our publisher, The Company of Biologists, has provided an apt environment to inspire biology and support biologists through our Workshops series. Read about the evolution of the Workshop series and revisit JEB's experience with hosting the first Global South Workshop.
Read & Publish Open Access publishing: what authors say

We have had great feedback from authors who have benefitted from our Read & Publish agreement with their institution and have been able to publish Open Access with us without paying an APC. Read what they had to say.
Fast & Fair peer review

Our sister journal Biology Open has recently launched the next phase of their Fast & Fair peer review initiative: offering high-quality peer review within 7 working days. To learn more about BiO’s progress and future plans, read the Editorial by Daniel Gorelick, or visit the Fast & Fair peer review page.
A new perspective on disease research
DMM publishes perspectives - peer-reviewed articles that provide expert analysis of a topic important to the disease research community. Read our collection from authors presenting new or potentially controversial ideas or hypotheses, to help address future challenges and forge new directions.
Other journals from
The Company of Biologists